Skip to main content
Mark Joseph Eliason
Rating: 5.0 of 5
( out of 943 reviews )

Mark Joseph Eliason, MD

Languages spoken: English

Clinical Locations

Primary Location

Midvalley Health Center

243 East 6100 South
Murray , UT 84107

University of Utah Hospital

Dermatology, Area E
50 N Medical Dr
Salt Lake City , UT 84132

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 943 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    My favorite. Like everything about him. Personal approach, his expertise, his results

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    Professional and genuinely compassionate. I trust his judgment and care implicitly.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    A VERY TALENTED,CARING DOCTOR.

    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Superb! Thanks!

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    I appreciate that Dr. Eliason is respectful in giving me privacy, even during my exam. He doesnt seem rushed, & is careful to answer all of my questions. I know I can trust him with the treatment I receive. I also appreciate that he gives me choices in my treatment & care. It means a lot that he listens to my concerns.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    Excelant

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
    Rating: 5 out of 5

    Dr. Eliason makes every visit comfortable along with his staff.

    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    This doctor is simply one of he best Ive ever encountered among many; its no wonder he also teaches and the School of Medicine. I imagine his lectures are so clear and precise.

    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    An outstanding physician.

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification and Academic Information

    Academic Departments Dermatology -Professor (Clinical)
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Undergraduate Molecular Biology - Brigham Young University B.S.
    Professional Medical Medicine - University of California - Irvine M.D.
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Research Fellow Familial Melanoma - Huntsman Cancer Institute Research Fellow
    Residency Dermatology - University of Utah School of Medicine Resident

    Selected Publications

    Journal Article

    1. Pho LN, Smith FJ, Konecki D, Bale S, McLean WH, Cohen B, Eliason MJ, Leachman SA (2011). Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. Arch Dermatol, 147(9), 1077-80. (Read full publication)
    2. Eliason MJ, Bowen GM, Bowen AR, Hazzard L, Samlowski WE (2009). Primary Treatment of Verrucous Carcinoma of the Penis with 5-fluorouracil, cis-diamino-dichloro platinum and Radiation Therapy Arch Derm). Arch Dermatol, 145(11), 1291.
    3. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL (2011). Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol, 64(6), 1221-2. (Read full publication)
    4. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol, 67(4), 680-6. (Read full publication)
    5. Clark JJ, Woodcock A, Cipriano SD, Hyde MA, Edwards SL, Frost CJ, Eliason MJ (2016). Community perceptions about the use of black salve. J Am Acad Dermatol, 74(5), 1021-3. (Read full publication)
    6. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol, 126(3), 660-6. (Read full publication)
    7. Larson AA, Leachman SA, Eliason MJ, Cannon-Albright LA (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol, 127(1), 183-8. (Read full publication)
    8. McLean WH, Hansen CD, Eliason MJ, Smith FJ (2011). The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol, 131(5), 1015-7. (Read full publication)
    9. Eliason MJ, Sontheimer RD (2015). How to reduce out-of-pocket costs for prescription medications.LID - 13030/qt5bk5n1vj [pii]. Dermatol Online J, 21(6). (Read full publication)
    10. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. (Read full publication)
    11. Pho LN, Eliason MJ, Regruto M, Hull CM, Powell D (2011). Treatment of chronic urticaria with colchicine. Journal of drugs in dermatology, 10(12), 1423-8. (Read full publication)
    12. Forbes B, Secrest AM, Hand MQ, Eliason M (2018). Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study. The Journal of clinical and aesthetic dermatology, 11(7), 36-39. (Read full publication)
    13. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest A (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA dermatology, 156(10), 1074-1078. (Read full publication)

    Review

    1. Leachman SA, Jackson R, Eliason MJ, Larson AA, Bolognia JL (2007). Management of melanoma during pregnancy. [Review]. Dermatol Nurs, 19, (2), 145-52, 161. (Read full publication)
    2. Millsop JW, Heller MM, Eliason MJ, Murase JE (2013). Dermatological medication effects on male fertility. [Review]. Dermatol Ther, 26, (4), 337-46. (Read full publication)

    Case Report

    1. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, Leachman SA (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol, 143(11), 1409-12. (Read full publication)

    Letter

    1. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Gleich GJ, Powell DL (2016). The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. [Letter to the editor]. J Am Acad Dermatol, 74(6), 1274-6. (Read full publication)
    2. Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris L (2016). Patient Preferences During Skin Cancer Screening Examination. JAMA dermatology, 152(9), 1052-4. (Read full publication)
    3. Eliason M, Bowen G, Bowen A, Hazard L, Samlowski (2009). Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Archives of dermatology, 145(8), 950-2. (Read full publication)